These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia]. Iványi JL; Marton E; Plander M Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365 [TBL] [Abstract][Full Text] [Related]
10. [Research progress on molecular pathogenesis of myeloproliferative neoplasms]. Liu L; Xiao ZJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):239-43. PubMed ID: 21362261 [TBL] [Abstract][Full Text] [Related]
11. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection]. Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140 [TBL] [Abstract][Full Text] [Related]
12. Advances in understanding and management of myeloproliferative neoplasms. Vannucchi AM; Guglielmelli P; Tefferi A CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682 [TBL] [Abstract][Full Text] [Related]
13. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Tefferi A; Thiele J; Vardiman JW Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396 [TBL] [Abstract][Full Text] [Related]
14. The role of beta-catenin in chronic myeloproliferative disorders. Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646 [TBL] [Abstract][Full Text] [Related]
15. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Baxter EJ; Scott LM; Campbell PJ; East C; Fourouclas N; Swanton S; Vassiliou GS; Bench AJ; Boyd EM; Curtin N; Scott MA; Erber WN; Green AR; Lancet; 2005 Mar 19-25; 365(9464):1054-61. PubMed ID: 15781101 [TBL] [Abstract][Full Text] [Related]
17. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants. Vardiman J; Hyjek E Hematology Am Soc Hematol Educ Program; 2011; 2011():250-6. PubMed ID: 22160042 [TBL] [Abstract][Full Text] [Related]
18. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Michiels JJ; Berneman Z; Schroyens W; De Raeve H Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092 [TBL] [Abstract][Full Text] [Related]